-
1
-
-
0032495530
-
A serine/threonine kinase gene defective in Peutz-Jeghers syndrome
-
Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391: 184-87.
-
(1998)
Nature
, vol.391
, pp. 184-187
-
-
Hemminki, A.1
Markie, D.2
Tomlinson, I.3
-
2
-
-
0031012344
-
Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis
-
Hemminki A, Tomlinson I, Markie D, et al. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 1997; 15: 87-90.
-
(1997)
Nat Genet
, vol.15
, pp. 87-90
-
-
Hemminki, A.1
Tomlinson, I.2
Markie, D.3
-
4
-
-
37149042642
-
A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome
-
Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007; 26: 7825-32.
-
(2007)
Oncogene
, vol.26
, pp. 7825-7832
-
-
Sanchez-Cespedes, M.1
-
5
-
-
0031974516
-
Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase
-
Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18: 38-43.
-
(1998)
Nat Genet
, vol.18
, pp. 38-43
-
-
Jenne, D.E.1
Reimann, H.2
Nezu, J.3
-
6
-
-
0038614742
-
Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD
-
Baas AF, Boudeau J, Sapkota GP, et al. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J 2003; 22: 3062-72.
-
(2003)
EMBO J
, vol.22
, pp. 3062-3072
-
-
Baas, A.F.1
Boudeau, J.2
Sapkota, G.P.3
-
7
-
-
1842581909
-
Comprehensive proteomic analysis of human Par protein complexes reveals an interconnected protein network
-
Brajenovic M, Joberty G, Küster B, Bouwmeester T, Drewes G. Comprehensive proteomic analysis of human Par protein complexes reveals an interconnected protein network. J Biol Chem 2004; 279: 12804-11.
-
(2004)
J Biol Chem
, vol.279
, pp. 12804-12811
-
-
Brajenovic, M.1
Joberty, G.2
Küster, B.3
Bouwmeester, T.4
Drewes, G.5
-
8
-
-
0141753981
-
MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm
-
Boudeau J, Baas AF, Deak M, et al. MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 2003; 22: 5102-14.
-
(2003)
EMBO J
, vol.22
, pp. 5102-5114
-
-
Boudeau, J.1
Baas, A.F.2
Deak, M.3
-
9
-
-
0345107247
-
Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade
-
Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.
-
(2003)
J Biol
, vol.2
, pp. 28
-
-
Hawley, S.A.1
Boudeau, J.2
Reid, J.L.3
-
10
-
-
10744230065
-
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
-
Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003; 13: 2004-08.
-
(2003)
Curr Biol
, vol.13
, pp. 2004-2008
-
-
Woods, A.1
Johnstone, S.R.2
Dickerson, K.3
-
11
-
-
1542618348
-
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress
-
Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004; 101: 3329-35.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 3329-3335
-
-
Shaw, R.J.1
Kosmatka, M.2
Bardeesy, N.3
-
12
-
-
12144287284
-
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1
-
Lizcano JM, Göransson O, Toth R, et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 2004; 23: 833-43.
-
(2004)
EMBO J
, vol.23
, pp. 833-843
-
-
Lizcano, J.M.1
Göransson, O.2
Toth, R.3
-
13
-
-
84876320551
-
LKB1 and AMPK and the cancermetabolism link-ten years after
-
Hardie DG, Alessi DR. LKB1 and AMPK and the cancermetabolism link-ten years after. BMC Biol 2013; 11: 36.
-
(2013)
BMC Biol
, vol.11
, pp. 36
-
-
Hardie, D.G.1
Alessi, D.R.2
-
14
-
-
34547926839
-
LKB1 modulates lung cancer differentiation and metastasis
-
Ji H, Ramsey MR, Hayes DN, Fan C, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-10.
-
(2007)
Nature
, vol.448
, pp. 807-810
-
-
Ji, H.1
Ramsey, M.R.2
Hayes, D.N.3
Fan, C.4
-
15
-
-
33746905916
-
LKB1 mutation in large cell carcinoma of the lung
-
Zhong D, Guo L, de Aguirre I, et al. LKB1 mutation in large cell carcinoma of the lung. Lung Cancer 2006; 53: 285-94.
-
(2006)
Lung Cancer
, vol.53
, pp. 285-294
-
-
Zhong, D.1
Guo, L.2
de Aguirre, I.3
-
16
-
-
77249121152
-
Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells
-
McCabe MT, Powell DR, Zhou W, Vertino PM. Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. Cancer Genet Cytogenet 2010; 197: 130-41.
-
(2010)
Cancer Genet Cytogenet
, vol.197
, pp. 130-141
-
-
McCabe, M.T.1
Powell, D.R.2
Zhou, W.3
Vertino, P.M.4
-
17
-
-
64549113040
-
Somatic LKB1 mutations promote cervical cancer progression
-
Wingo SN, Gallardo TD, Akbay EA, et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS One 2009; 4: e5137.
-
(2009)
PLoS One
, vol.4
-
-
Wingo, S.N.1
Gallardo, T.D.2
Akbay, E.A.3
-
18
-
-
84856215097
-
Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion
-
Gu Y, Lin S, Li JL, et al. Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene 2012; 31: 469-79.
-
(2012)
Oncogene
, vol.31
, pp. 469-479
-
-
Gu, Y.1
Lin, S.2
Li, J.L.3
-
19
-
-
0037068461
-
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation
-
Bardeesy N, Sinha M, Hezel AF, et al. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 2002; 419: 162-7.
-
(2002)
Nature
, vol.419
, pp. 162-167
-
-
Bardeesy, N.1
Sinha, M.2
Hezel, A.F.3
-
20
-
-
0036645286
-
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung
-
Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002; 62: 3659-62.
-
(2002)
Cancer Res
, vol.62
, pp. 3659-3662
-
-
Sanchez-Cespedes, M.1
Parrella, P.2
Esteller, M.3
-
21
-
-
78049515002
-
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases
-
Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010; 28: 4616-20.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4616-4620
-
-
Sun, Y.1
Ren, Y.2
Fang, Z.3
-
22
-
-
77949469320
-
Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy
-
Contreras CM, Akbay EA, Gallardo TD, et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech 2010; 3: 181-93.
-
(2010)
Dis Model Mech
, vol.3
, pp. 181-193
-
-
Contreras, C.M.1
Akbay, E.A.2
Gallardo, T.D.3
-
23
-
-
38849193504
-
Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas
-
Contreras CM, Gurumurthy S, Haynie JM, et al. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res 2008; 68: 759-66.
-
(2008)
Cancer Res
, vol.68
, pp. 759-766
-
-
Contreras, C.M.1
Gurumurthy, S.2
Haynie, J.M.3
-
24
-
-
67749111502
-
The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression
-
Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-75.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 563-575
-
-
Shackelford, D.B.1
Shaw, R.J.2
-
25
-
-
0035980097
-
LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest
-
Marignani PA, Kanai F, Carpenter CL. LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest. J Biol Chem 2001; 276: 32415-8.
-
(2001)
J Biol Chem
, vol.276
, pp. 32415-32418
-
-
Marignani, P.A.1
Kanai, F.2
Carpenter, C.L.3
-
26
-
-
1542777034
-
Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD
-
Baas AF, Kuipers J, van der Wel NN, et al. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004; 116: 457-66.
-
(2004)
Cell
, vol.116
, pp. 457-466
-
-
Baas, A.F.1
Kuipers, J.2
van der Wel, N.N.3
-
27
-
-
33846521353
-
Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase
-
Zheng B, Cantley LC. Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase. Proc Natl Acad Sci U S A 2007; 104: 819-22.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 819-822
-
-
Zheng, B.1
Cantley, L.C.2
-
28
-
-
0034964446
-
The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death
-
Karuman P, Gozani O, Odze RD, et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell 2001; 7: 1307-19.
-
(2001)
Mol Cell
, vol.7
, pp. 1307-1319
-
-
Karuman, P.1
Gozani, O.2
Odze, R.D.3
-
29
-
-
78649874959
-
Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells
-
Gan B, Hu J, Jiang S, et al. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 2010; 468: 701-4.
-
(2010)
Nature
, vol.468
, pp. 701-704
-
-
Gan, B.1
Hu, J.2
Jiang, S.3
-
30
-
-
78649851511
-
The Lkb1 metabolic sensor maintains haematopoietic stem cell survival
-
Gurumurthy S, Xie SZ, Alagesan B, et al. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 2010; 468: 659-63.
-
(2010)
Nature
, vol.468
, pp. 659-663
-
-
Gurumurthy, S.1
Xie, S.Z.2
Alagesan, B.3
-
31
-
-
78649811793
-
Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells
-
Nakada D, Saunders TL, Morrison SJ. Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature 2010; 468: 653-8.
-
(2010)
Nature
, vol.468
, pp. 653-658
-
-
Nakada, D.1
Saunders, T.L.2
Morrison, S.J.3
-
32
-
-
33847072201
-
AMP-activated protein kinase as a drug target
-
Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007; 47: 185-210.
-
(2007)
Annu Rev Pharmacol Toxicol
, vol.47
, pp. 185-210
-
-
Hardie, D.G.1
-
33
-
-
80053035284
-
AMP-activated protein kinase: An energy sensor that regulates all aspects of cell function
-
Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011; 25: 1895-908.
-
(2011)
Genes Dev
, vol.25
, pp. 1895-1908
-
-
Hardie, D.G.1
-
34
-
-
56049112796
-
Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes
-
Scott JW, van Denderen BJ, Jorgensen SB, et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem Biol 2008; 15: 1220-30.
-
(2008)
Chem Biol
, vol.15
, pp. 1220-1230
-
-
Scott, J.W.1
van Denderen, B.J.2
Jorgensen, S.B.3
-
35
-
-
34848850156
-
An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans
-
Greer EL, Dowlatshahi D, Banko MR, et al. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr Biol 2007; 17: 1646-56.
-
(2007)
Curr Biol
, vol.17
, pp. 1646-1656
-
-
Greer, E.L.1
Dowlatshahi, D.2
Banko, M.R.3
-
36
-
-
33745840203
-
5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments
-
Laderoute KR, Amin K, Calaoagan JM, et al. 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006; 26: 5336-47.
-
(2006)
Mol Cell Biol
, vol.26
, pp. 5336-5347
-
-
Laderoute, K.R.1
Amin, K.2
Calaoagan, J.M.3
-
37
-
-
77956401999
-
Metformin and other biguanides in oncology: Advancing the research agenda
-
Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 2010; 3: 1060-5.
-
(2010)
Cancer Prev Res (Phila)
, vol.3
, pp. 1060-1065
-
-
Pollak, M.1
-
38
-
-
28844433635
-
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin
-
Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-6.
-
(2005)
Science
, vol.310
, pp. 1642-1646
-
-
Shaw, R.J.1
Lamia, K.A.2
Vasquez, D.3
-
39
-
-
84862908818
-
AMPK and mTOR in cellular energy homeostasis and drug targets
-
Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 2012; 52: 381-400.
-
(2012)
Annu Rev Pharmacol Toxicol
, vol.52
, pp. 381-400
-
-
Inoki, K.1
Kim, J.2
Guan, K.L.3
-
40
-
-
79551598347
-
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
-
Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011; 13: 132-41.
-
(2011)
Nat Cell Biol
, vol.13
, pp. 132-141
-
-
Kim, J.1
Kundu, M.2
Viollet, B.3
Guan, K.L.4
-
41
-
-
80052511813
-
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
-
Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011; 13: 1016-23.
-
(2011)
Nat Cell Biol
, vol.13
, pp. 1016-1023
-
-
Mihaylova, M.M.1
Shaw, R.J.2
-
42
-
-
79251587803
-
Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy
-
Egan DF, Shackelford DB, Mihaylova MM, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011; 331: 456-61.
-
(2011)
Science
, vol.331
, pp. 456-461
-
-
Egan, D.F.1
Shackelford, D.B.2
Mihaylova, M.M.3
-
43
-
-
84863535512
-
p70S6 kinase phosphorylates AMPK on serine 491 to mediate leptin's effect on food intake
-
Dagon Y, Hur E, Zheng B, Wellenstein K, Cantley LC, Kahn BB. p70S6 kinase phosphorylates AMPK on serine 491 to mediate leptin's effect on food intake. Cell Metab 2012; 16: 104-12.
-
(2012)
Cell Metab
, vol.16
, pp. 104-112
-
-
Dagon, Y.1
Hur, E.2
Zheng, B.3
Wellenstein, K.4
Cantley, L.C.5
Kahn, B.B.6
-
44
-
-
79953755370
-
AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice
-
Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13: 376-88.
-
(2011)
Cell Metab
, vol.13
, pp. 376-388
-
-
Li, Y.1
Xu, S.2
Mihaylova, M.M.3
-
45
-
-
33749349202
-
Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice
-
Zang M, Xu S, Maitland-Toolan KA, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006; 55: 2180-91.
-
(2006)
Diabetes
, vol.55
, pp. 2180-2191
-
-
Zang, M.1
Xu, S.2
Maitland-Toolan, K.A.3
-
46
-
-
9144271181
-
AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulinresistant human HepG2 cells
-
Zang M, Zuccollo A, Hou X, et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulinresistant human HepG2 cells. J Biol Chem 2004; 279: 47898-905.
-
(2004)
J Biol Chem
, vol.279
, pp. 47898-47905
-
-
Zang, M.1
Zuccollo, A.2
Hou, X.3
-
47
-
-
79251556232
-
Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation
-
Vingtdeux V, Chandakkar P, Zhao H, d'Abramo C, Davies P, Marambaud P. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J 2011; 25: 219-31.
-
(2011)
FASEB J
, vol.25
, pp. 219-231
-
-
Vingtdeux, V.1
Chandakkar, P.2
Zhao, H.3
d'Abramo, C.4
Davies, P.5
Marambaud, P.6
-
48
-
-
3042818799
-
Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome
-
Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 2004; 18: 1533-8.
-
(2004)
Genes Dev
, vol.18
, pp. 1533-1538
-
-
Corradetti, M.N.1
Inoki, K.2
Bardeesy, N.3
DePinho, R.A.4
Guan, K.L.5
-
49
-
-
33748153690
-
TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth
-
Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126: 955-68.
-
(2006)
Cell
, vol.126
, pp. 955-968
-
-
Inoki, K.1
Ouyang, H.2
Zhu, T.3
-
50
-
-
84859778293
-
mTOR signaling in growth control and disease
-
Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-93.
-
(2012)
Cell
, vol.149
, pp. 274-293
-
-
Laplante, M.1
Sabatini, D.M.2
-
51
-
-
42949139481
-
AMPK phosphorylation of raptor mediates a metabolic checkpoint
-
Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-26.
-
(2008)
Mol Cell
, vol.30
, pp. 214-226
-
-
Gwinn, D.M.1
Shackelford, D.B.2
Egan, D.F.3
Mihaylova, M.M.4
Mery, A.5
Vasquez, D.S.6
Turk, B.E.7
Shaw, R.J.8
-
52
-
-
67650480092
-
mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
-
Shackelford DB, Vasquez DS, Corbeil J, et al. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci USA 2009; 106: 11137-42.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 11137-11142
-
-
Shackelford, D.B.1
Vasquez, D.S.2
Corbeil, J.3
-
53
-
-
84872159532
-
AMPK is a negative regulator of the Warburg effect and suppresses tumor growth In vivo
-
Faubert B, Boily G, Izreig S, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth In vivo. Cell Metab 2013; 17: 113-24.
-
(2013)
Cell Metab
, vol.17
, pp. 113-124
-
-
Faubert, B.1
Boily, G.2
Izreig, S.3
-
54
-
-
39749102904
-
Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling
-
Wei C, Amos CI, Zhang N, et al. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin Cancer Res 2008; 14: 1167-71.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 1167-1171
-
-
Wei, C.1
Amos, C.I.2
Zhang, N.3
-
55
-
-
84863763440
-
AMPK regulates NADPH homeostasis to promote tumor cell survival during energy stress
-
Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumor cell survival during energy stress. Nature 2012; 485: 661-5.
-
(2012)
Nature
, vol.485
, pp. 661-665
-
-
Jeon, S.M.1
Chandel, N.S.2
Hay, N.3
-
56
-
-
84877851087
-
AMPK: A contextual oncogene or tumor suppressor?
-
Liang J, Mills GB. AMPK: a contextual oncogene or tumor suppressor? Cancer Res 2013; 73: 2929-35.
-
(2013)
Cancer Res
, vol.73
, pp. 2929-2935
-
-
Liang, J.1
Mills, G.B.2
-
57
-
-
84876936567
-
AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors
-
Ríos M, Foretz M, Viollet B, et al. AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer Res 2013; 73: 2628-38.
-
(2013)
Cancer Res
, vol.73
, pp. 2628-2638
-
-
Ríos, M.1
Foretz, M.2
Viollet, B.3
-
58
-
-
26444610333
-
LKB1 interacts with and phosphorylates PTEN: A functional link between two proteins involved in cancer predisposing syndromes
-
Mehenni H, Lin-Marq N, Buchet-Poyau K, et al. LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Hum Mol Genet 2005; 14: 2209-19.
-
(2005)
Hum Mol Genet
, vol.14
, pp. 2209-2219
-
-
Mehenni, H.1
Lin-Marq, N.2
Buchet-Poyau, K.3
-
59
-
-
0037125996
-
Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis
-
Rossi DJ, Ylikorkala A, Korsisaari N, et al. Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. Proc Natl Acad Sci USA 2002; 99: 12327-32.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 12327-12332
-
-
Rossi, D.J.1
Ylikorkala, A.2
Korsisaari, N.3
-
60
-
-
35548952703
-
Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization
-
Partanen JI, Nieminen AI, Mäkelä TP, Klefstrom J. Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization. Proc Natl Acad Sci USA 2007; 104: 14694-9.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 14694-14699
-
-
Partanen, J.I.1
Nieminen, A.I.2
Mäkelä, T.P.3
Klefstrom, J.4
-
61
-
-
0037096833
-
Growth arrest by the LKB1 tumor suppressor: Induction of p21(WAF1/CIP1)
-
Tiainen M, Vaahtomeri K, Ylikorkala A, Makela TP. Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). Hum Mol Genet 2002; 11: 1497-504.
-
(2002)
Hum Mol Genet
, vol.11
, pp. 1497-1504
-
-
Tiainen, M.1
Vaahtomeri, K.2
Ylikorkala, A.3
Makela, T.P.4
-
62
-
-
33947250696
-
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis
-
Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM, Mills GB. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9: 218-24.
-
(2007)
Nat Cell Biol
, vol.9
, pp. 218-224
-
-
Liang, J.1
Shao, S.H.2
Xu, Z.X.3
Hennessy, B.4
Ding, Z.5
Larrea, M.6
Kondo, S.7
Dumont, D.J.8
Gutterman, J.U.9
Walker, C.L.10
Slingerland, J.M.11
Mills, G.B.12
-
63
-
-
34250793435
-
LKB1 catalytically deficient mutants enhance cyclin D1 expression
-
Scott KD, Nath-Sain S, Agnew MD, Marignani PA. LKB1 catalytically deficient mutants enhance cyclin D1 expression. Cancer Res 2007; 67: 5622-7.
-
(2007)
Cancer Res
, vol.67
, pp. 5622-5627
-
-
Scott, K.D.1
Nath-Sain, S.2
Agnew, M.D.3
Marignani, P.A.4
-
64
-
-
34250827107
-
Energy-dependent regulation of cell structure by AMP-activated protein kinase
-
Lee JH, Koh H, Kim M, et al. Energy-dependent regulation of cell structure by AMP-activated protein kinase. Nature 2007; 447: 1017-20.
-
(2007)
Nature
, vol.447
, pp. 1017-1020
-
-
Lee, J.H.1
Koh, H.2
Kim, M.3
-
65
-
-
34247478454
-
LKB1/STRAD promotes axon initiation during neuronal polarization
-
Shelly M, Cancedda L, Heilshorn S, Sumbre G, Poo MM. LKB1/STRAD promotes axon initiation during neuronal polarization. Cell 2007; 129: 565-77.
-
(2007)
Cell
, vol.129
, pp. 565-577
-
-
Shelly, M.1
Cancedda, L.2
Heilshorn, S.3
Sumbre, G.4
Poo, M.M.5
-
66
-
-
34247511497
-
LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons
-
Barnes AP, Lilley BN, Pan YA, et al. LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell 2007; 129: 549-63.
-
(2007)
Cell
, vol.129
, pp. 549-563
-
-
Barnes, A.P.1
Lilley, B.N.2
Pan, Y.A.3
-
67
-
-
3042649049
-
LKB1 kinase: Master and commander of metabolism and polarity
-
Spicer J, Ashworth A. LKB1 kinase: master and commander of metabolism and polarity. Curr Biol 2004; 14: R383-5.
-
(2004)
Curr Biol
, vol.14
, pp. 383-385
-
-
Spicer, J.1
Ashworth, A.2
-
68
-
-
77956906920
-
Regulation of bile canalicular network formation and maintenance by AMP-activated protein kinase and LKB1
-
Fu D, Wakabayashi Y, Ido Y, Lippincott-Schwartz J, Arias IM. Regulation of bile canalicular network formation and maintenance by AMP-activated protein kinase and LKB1. J Cell Sci 2010; 123: 3294-302.
-
(2010)
J Cell Sci
, vol.123
, pp. 3294-3302
-
-
Fu, D.1
Wakabayashi, Y.2
Ido, Y.3
Lippincott-Schwartz, J.4
Arias, I.M.5
-
69
-
-
33751204464
-
AMP-activated protein kinase regulates the assembly of epithelial tight junctions
-
Zhang L, Li J, Young LH, Caplan MJ. AMP-activated protein kinase regulates the assembly of epithelial tight junctions. Proc Natl Acad Sci USA 2006; 103: 17272-7.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 17272-17277
-
-
Zhang, L.1
Li, J.2
Young, L.H.3
Caplan, M.J.4
-
70
-
-
64549137929
-
Mst4 and Ezrin induce brush borders downstream of the Lkb1/Strad/Mo25 polarization complex
-
ten Klooster JP, Jansen M, Yuan J, et al. Mst4 and Ezrin induce brush borders downstream of the Lkb1/Strad/Mo25 polarization complex. Dev Cell 2009; 16: 551-62.
-
(2009)
Dev Cell
, vol.16
, pp. 551-562
-
-
ten Klooster, J.P.1
Jansen, M.2
Yuan, J.3
-
71
-
-
84864869731
-
Rap2A links intestinal cell polarity to brush border formation
-
Gloerich M, ten Klooster JP, Vliem MJ, et al. Rap2A links intestinal cell polarity to brush border formation. Nat Cell Biol 2012; 14: 793-801.
-
(2012)
Nat Cell Biol
, vol.14
, pp. 793-801
-
-
Gloerich, M.1
ten Klooster, J.P.2
Vliem, M.J.3
-
72
-
-
78149259013
-
Primary cilia regulate mTORC1 activity and cell size through Lkb1
-
Boehlke C, Kotsis F, Patel V, et al. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol 2010; 12: 1115-22.
-
(2010)
Nat Cell Biol
, vol.12
, pp. 1115-1122
-
-
Boehlke, C.1
Kotsis, F.2
Patel, V.3
-
73
-
-
58149270886
-
Regulation of LKB1/STRAD localization and function by E-cadherin
-
Sebbagh M, Santoni MJ, Hall B, Borg JP, Schwartz MA. Regulation of LKB1/STRAD localization and function by E-cadherin. Curr Biol 2009; 19: 37-42.
-
(2009)
Curr Biol
, vol.19
, pp. 37-42
-
-
Sebbagh, M.1
Santoni, M.J.2
Hall, B.3
Borg, J.P.4
Schwartz, M.A.5
-
74
-
-
84655169623
-
Epithelial cell polarity, stem cells and cancer
-
Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer 2011; 12: 23-38.
-
(2011)
Nat Rev Cancer
, vol.12
, pp. 23-38
-
-
Martin-Belmonte, F.1
Perez-Moreno, M.2
-
75
-
-
33748747706
-
Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase In vitro
-
Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase In vitro. J Biol Chem 2006; 281: 25336-43.
-
(2006)
J Biol Chem
, vol.281
, pp. 25336-25343
-
-
Momcilovic, M.1
Hong, S.P.2
Carlson, M.3
-
76
-
-
23844471263
-
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases
-
Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, Witters LA. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 2005; 280: 29060-6.
-
(2005)
J Biol Chem
, vol.280
, pp. 29060-29066
-
-
Hurley, R.L.1
Anderson, K.A.2
Franzone, J.M.3
Kemp, B.E.4
Means, A.R.5
Witters, L.A.6
-
77
-
-
23044437445
-
Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells
-
Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR, Carlson M, Carling D. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005; 2: 21-33.
-
(2005)
Cell Metab
, vol.2
, pp. 21-33
-
-
Woods, A.1
Dickerson, K.2
Heath, R.3
Hong, S.P.4
Momcilovic, M.5
Johnstone, S.R.6
Carlson, M.7
Carling, D.8
-
78
-
-
76449101125
-
Differential requirements for STRAD in LKB1-dependent functions in C. elegans
-
Narbonne P, Hyenne V, Li S, Labbé JC, Roy R. Differential requirements for STRAD in LKB1-dependent functions in C. elegans. Development 2010; 137: 661-70.
-
(2010)
Development
, vol.137
, pp. 661-670
-
-
Narbonne, P.1
Hyenne, V.2
Li, S.3
Labbé, J.C.4
Roy, R.5
-
79
-
-
77957879994
-
Lymphocytes accelerate epithelial tight junction assembly: Role of AMP-activated protein kinase (AMPK)
-
Tang XX, Chen H, Yu S, Zhang L, Caplan MJ, Chan HC. Lymphocytes accelerate epithelial tight junction assembly: role of AMP-activated protein kinase (AMPK). PLoS One 2010; 5: e12343.
-
(2010)
PLoS One
, vol.5
-
-
Tang, X.X.1
Chen, H.2
Yu, S.3
Zhang, L.4
Caplan, M.J.5
Chan, H.C.6
-
80
-
-
35748943872
-
Dialogue between LKB1 and AMPK: A hot topic at the cellular pole
-
Forcet C, Billaud M. Dialogue between LKB1 and AMPK: a hot topic at the cellular pole. Sci STKE 2007; 2007(404): pe51.
-
(2007)
Sci STKE
, vol.2007
, Issue.404
-
-
Forcet, C.1
Billaud, M.2
-
81
-
-
19944413010
-
Genome-wide survey of protein kinases required for cell cycle progression
-
Bettencourt-Dias M, Giet R, Sinka R, et al. Genome-wide survey of protein kinases required for cell cycle progression. Nature 2004; 432: 980-7.
-
(2004)
Nature
, vol.432
, pp. 980-987
-
-
Bettencourt-Dias, M.1
Giet, R.2
Sinka, R.3
-
82
-
-
84864009034
-
The LKB1 tumor suppressor controls spindle orientation and localization of activated AMPK in mitotic epithelial cells
-
Wei C, Bhattaram VK, Igwe JC, Fleming E, Tirnauer JS. The LKB1 tumor suppressor controls spindle orientation and localization of activated AMPK in mitotic epithelial cells. PLoS One 2012; 7: e41118.
-
(2012)
PLoS One
, vol.7
-
-
Wei, C.1
Bhattaram, V.K.2
Igwe, J.C.3
Fleming, E.4
Tirnauer, J.S.5
-
83
-
-
84355161919
-
Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis
-
Banko MR, Allen JJ, Schaffer BE, et al. Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell 2011; 44: 878-92.
-
(2011)
Mol Cell
, vol.44
, pp. 878-892
-
-
Banko, M.R.1
Allen, J.J.2
Schaffer, B.E.3
-
84
-
-
62449138276
-
Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKalphaThr172) in human cancer cells
-
Vazquez-Martin A, López-Bonet E, Oliveras-Ferraros C, Pérez-Martínez MC, Bernadó L, Menendez JA. Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKalphaThr172) in human cancer cells. Cell Cycle 2009; 8: 788-91.
-
(2009)
Cell Cycle
, vol.8
, pp. 788-791
-
-
Vazquez-Martin, A.1
López-Bonet, E.2
Oliveras-Ferraros, C.3
Pérez-Martínez, M.C.4
Bernadó, L.5
Menendez, J.A.6
-
85
-
-
10944257674
-
Crosslinks and crosstalk: Human cancer syndromes and DNA repair defects
-
Risinger MA, Groden J. Crosslinks and crosstalk: human cancer syndromes and DNA repair defects. Cancer Cell 2004; 6: 539-45.
-
(2004)
Cancer Cell
, vol.6
, pp. 539-545
-
-
Risinger, M.A.1
Groden, J.2
-
86
-
-
36749022214
-
The DNA damage response: Ten years after
-
Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007; 28: 739-45.
-
(2007)
Mol Cell
, vol.28
, pp. 739-745
-
-
Harper, J.W.1
Elledge, S.J.2
-
87
-
-
34249947699
-
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage
-
Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316: 1160-6.
-
(2007)
Science
, vol.316
, pp. 1160-1166
-
-
Matsuoka, S.1
Ballif, B.A.2
Smogorzewska, A.3
-
88
-
-
17644362355
-
DNA damage-induced association of ATM with its target proteins requires a protein interaction domain in the N terminus of ATM
-
Fernandes N, Sun Y, Chen S, et al. DNA damage-induced association of ATM with its target proteins requires a protein interaction domain in the N terminus of ATM. J Biol Chem 2005; 280: 15158-64.
-
(2005)
J Biol Chem
, vol.280
, pp. 15158-15164
-
-
Fernandes, N.1
Sun, Y.2
Chen, S.3
-
89
-
-
0036901639
-
Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366
-
Sapkota GP, Deak M, Kieloch A, et al. Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366. Biochem J 2002; 368(Pt 2): 507-16.
-
(2002)
Biochem J
, vol.368
, Issue.PART 2
, pp. 507-516
-
-
Sapkota, G.P.1
Deak, M.2
Kieloch, A.3
-
91
-
-
77749233738
-
ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS
-
Alexander A, Cai SL, Kim J, et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA 2010; 107: 4153-8.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 4153-4158
-
-
Alexander, A.1
Cai, S.L.2
Kim, J.3
-
92
-
-
84862119127
-
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma
-
Liu W, Monahan KB, Pfefferle AD, et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 2012; 21: 751-64.
-
(2012)
Cancer Cell
, vol.21
, pp. 751-764
-
-
Liu, W.1
Monahan, K.B.2
Pfefferle, A.D.3
-
93
-
-
79251614530
-
Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelialmesenchymal transition in the mouse bladder
-
Shorning BY, Griffiths D, Clarke AR. Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelialmesenchymal transition in the mouse bladder. PLoS One 2011; 6: e16209.
-
(2011)
PLoS One
, vol.6
-
-
Shorning, B.Y.1
Griffiths, D.2
Clarke, A.R.3
-
94
-
-
77957021496
-
Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells
-
Roy BC, Kohno T, Iwakawa R, et al. Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells. Lung Cancer 2010; 70: 136-45.
-
(2010)
Lung Cancer
, vol.70
, pp. 136-145
-
-
Roy, B.C.1
Kohno, T.2
Iwakawa, R.3
-
95
-
-
70349565231
-
SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis
-
Cheng H, Liu P, Wang ZC, et al. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal 2009; 2: ra35.
-
(2009)
Sci Signal
, vol.2
-
-
Cheng, H.1
Liu, P.2
Wang, Z.C.3
-
96
-
-
84857043185
-
The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis
-
Ng TL, Leprivier G, Robertson MD, et al. The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. Cell Death Differ 2012; 19: 501-10.
-
(2012)
Cell Death Differ
, vol.19
, pp. 501-510
-
-
Ng, T.L.1
Leprivier, G.2
Robertson, M.D.3
-
97
-
-
78650488264
-
LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling
-
Gao Y, Xiao Q, Ma H, et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci USA 2010; 107: 18892-7.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 18892-18897
-
-
Gao, Y.1
Xiao, Q.2
Ma, H.3
-
98
-
-
39149083762
-
LKB1 deficiency sensitizes mice to carcinogeninduced tumorigenesis
-
Gurumurthy S, Hezel AF, Sahin E, Berger JH, Bosenberg MW, Bardeesy N. LKB1 deficiency sensitizes mice to carcinogeninduced tumorigenesis. Cancer Res 2008; 68: 55-63.
-
(2008)
Cancer Res
, vol.68
, pp. 55-63
-
-
Gurumurthy, S.1
Hezel, A.F.2
Sahin, E.3
Berger, J.H.4
Bosenberg, M.W.5
Bardeesy, N.6
-
99
-
-
34848861463
-
The energy sensor AMPactivated protein kinase directly regulates the mammalian FOXO3 transcription factor
-
Greer EL, Oskoui PR, Banko MR, et al. The energy sensor AMPactivated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 2007; 282: 30107-19.
-
(2007)
J Biol Chem
, vol.282
, pp. 30107-30119
-
-
Greer, E.L.1
Oskoui, P.R.2
Banko, M.R.3
-
100
-
-
33646376411
-
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
-
Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441: 475-82.
-
(2006)
Nature
, vol.441
, pp. 475-482
-
-
Yilmaz, O.H.1
Valdez, R.2
Theisen, B.K.3
-
101
-
-
78650866793
-
The tumor suppressor LKB1 emerges as a critical factor in hematopoietic stem cell biology
-
Krock B, Skuli N, Simon MC. The tumor suppressor LKB1 emerges as a critical factor in hematopoietic stem cell biology. Cell Metab 2011; 13: 8-10.
-
(2011)
Cell Metab
, vol.13
, pp. 8-10
-
-
Krock, B.1
Skuli, N.2
Simon, M.C.3
-
102
-
-
84859496182
-
LKB1 controls the pluripotent state of human embryonic stem cells
-
Lai D, Chen Y, Wang F, Jiang L, Wei C. LKB1 controls the pluripotent state of human embryonic stem cells. Cell Reprogram 2012; 14: 164-70.
-
(2012)
Cell Reprogram
, vol.14
, pp. 164-170
-
-
Lai, D.1
Chen, Y.2
Wang, F.3
Jiang, L.4
Wei, C.5
-
103
-
-
33744828352
-
Exonic STK11 deletions are not a rare cause of Peutz-Jeghers syndrome
-
Hearle NC, Rudd MF, Lim W, et al. Exonic STK11 deletions are not a rare cause of Peutz-Jeghers syndrome. J Med Genet 2006; 43: e15.
-
(2006)
J Med Genet
, vol.43
-
-
Hearle, N.C.1
Rudd, M.F.2
Lim, W.3
-
104
-
-
33745966059
-
LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome
-
Volikos E, Robinson J, Aittomaki K, et al. LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome. J Med Genet 2006; 43: e18.
-
(2006)
J Med Genet
, vol.43
-
-
Volikos, E.1
Robinson, J.2
Aittomaki, K.3
-
106
-
-
33744782567
-
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome
-
Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006; 12: 3209-15.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3209-3215
-
-
Hearle, N.1
Schumacher, V.2
Menko, F.H.3
-
107
-
-
34748845413
-
Prevalence and specificity of LKB1 genetic alterations in lung cancers
-
Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007; 26: 5911-8.
-
(2007)
Oncogene
, vol.26
, pp. 5911-5918
-
-
Matsumoto, S.1
Iwakawa, R.2
Takahashi, K.3
-
109
-
-
0034614637
-
The hallmarks of cancer
-
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
-
(2000)
Cell
, vol.100
, pp. 57-70
-
-
Hanahan, D.1
Weinberg, R.A.2
-
110
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
111
-
-
84862742039
-
Targeted therapy for patients with chronic myeloid leukemia: Clinical trial experience and challenges in intertrial comparisons
-
Tiu R, Kalaycio M. Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in intertrial comparisons. Leuk Lymphoma 2012; 53: 1263-72.
-
(2012)
Leuk Lymphoma
, vol.53
, pp. 1263-1272
-
-
Tiu, R.1
Kalaycio, M.2
-
113
-
-
84856693441
-
Mutant p53 protein, master regulator of human malignancies: A report on the Fifth Mutant p53 Workshop
-
Blandino G, Deppert W, Hainaut P, et al. Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death Differ 2012; 19: 180-3.
-
(2012)
Cell Death Differ
, vol.19
, pp. 180-183
-
-
Blandino, G.1
Deppert, W.2
Hainaut, P.3
-
115
-
-
0036949663
-
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database
-
Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002; 23: 2011-8.
-
(2002)
Carcinogenesis
, vol.23
, pp. 2011-2018
-
-
Bykov, V.J.1
Issaeva, N.2
Selivanova, G.3
Wiman, K.G.4
-
116
-
-
65449144050
-
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
-
Lambert JM, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15: 376-88.
-
(2009)
Cancer Cell
, vol.15
, pp. 376-388
-
-
Lambert, J.M.1
Gorzov, P.2
Veprintsev, D.B.3
-
117
-
-
84876976694
-
Targeting triple negative breast cancer: Is p53 the answer?
-
Turner N, Moretti E, Siclari O, et al. Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev 2013; 39: 541-50.
-
(2013)
Cancer Treat Rev
, vol.39
, pp. 541-550
-
-
Turner, N.1
Moretti, E.2
Siclari, O.3
-
119
-
-
84880352272
-
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
-
Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci USA 2013; 110: 11988-93.
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. 11988-11993
-
-
Pourdehnad, M.1
Truitt, M.L.2
Siddiqi, I.N.3
Ducker, G.S.4
Shokat, K.M.5
Ruggero, D.6
-
120
-
-
84880163379
-
Perspective: Combined forces
-
Sawyers CL. Perspective: combined forces. Nature 2013; 498: S7.
-
(2013)
Nature
, vol.498
-
-
Sawyers, C.L.1
-
121
-
-
65849278908
-
Finding and drugging the vulnerabilities of RASdependent cancers
-
Sawyers CL. Finding and drugging the vulnerabilities of RASdependent cancers. Cell 2009; 137: 796-8.
-
(2009)
Cell
, vol.137
, pp. 796-798
-
-
Sawyers, C.L.1
-
122
-
-
76449110054
-
Synthetic lethality: A framework for the development of wiser cancer therapeutics
-
Kaelin WG Jr. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med 2009; 1: 99.
-
(2009)
Genome Med
, vol.1
, pp. 99
-
-
Kaelin Jr., W.G.1
-
123
-
-
84872387485
-
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
-
Corcoran RB, Cheng KA, Hata AN, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013; 23: 121-8.
-
(2013)
Cancer Cell
, vol.23
, pp. 121-128
-
-
Corcoran, R.B.1
Cheng, K.A.2
Hata, A.N.3
-
124
-
-
65849111219
-
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells
-
Scholl C, Fröhling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137: 821-34.
-
(2009)
Cell
, vol.137
, pp. 821-834
-
-
Scholl, C.1
Fröhling, S.2
Dunn, I.F.3
-
125
-
-
66149091940
-
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
-
Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009; 137: 835-48.
-
(2009)
Cell
, vol.137
, pp. 835-848
-
-
Luo, J.1
Emanuele, M.J.2
Li, D.3
-
126
-
-
79251564088
-
A review of PARP inhibitors: From bench to bedside
-
Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011; 22: 268-79.
-
(2011)
Ann Oncol
, vol.22
, pp. 268-279
-
-
Underhill, C.1
Toulmonde, M.2
Bonnefoi, H.3
-
127
-
-
69549145898
-
The potential role and application of PARP inhibitors in cancer treatment
-
Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009; 89: 23-40.
-
(2009)
Br Med Bull
, vol.89
, pp. 23-40
-
-
Chalmers, A.J.1
-
128
-
-
77950023283
-
PARP inhibition: PARP1 and beyond
-
Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10: 293-301.
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 293-301
-
-
Rouleau, M.1
Patel, A.2
Hendzel, M.J.3
Kaufmann, S.H.4
Poirier, G.G.5
-
129
-
-
17244375049
-
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
-
Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
-
(2005)
Nature
, vol.434
, pp. 913-917
-
-
Bryant, H.E.1
Schultz, N.2
Thomas, H.D.3
-
130
-
-
17244373777
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
-
Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
-
(2005)
Nature
, vol.434
, pp. 917-921
-
-
Farmer, H.1
McCabe, N.2
Lord, C.J.3
-
131
-
-
77954032829
-
Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
-
Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-9.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2512-2519
-
-
Fong, P.C.1
Yap, T.A.2
Boss, D.S.3
-
132
-
-
84954358647
-
A highthroughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
-
Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A. A highthroughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008; 7: 2010-9.
-
(2008)
DNA Repair (Amst)
, vol.7
, pp. 2010-2019
-
-
Lord, C.J.1
McDonald, S.2
Swift, S.3
Turner, N.C.4
Ashworth, A.5
-
133
-
-
43249085571
-
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
-
Turner NC, Lord CJ, Iorns E, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008; 27: 1368-77.
-
(2008)
EMBO J
, vol.27
, pp. 1368-1377
-
-
Turner, N.C.1
Lord, C.J.2
Iorns, E.3
-
134
-
-
77149157867
-
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
-
Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315-22.
-
(2009)
EMBO Mol Med
, vol.1
, pp. 315-322
-
-
Mendes-Pereira, A.M.1
Martin, S.A.2
Brough, R.3
-
135
-
-
77954358148
-
PTEN loss compromises homologous recombination repair in astrocytes: Implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors
-
McEllin B, Camacho CV, Mukherjee B, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010; 70: 5457-64.
-
(2010)
Cancer Res
, vol.70
, pp. 5457-5464
-
-
McEllin, B.1
Camacho, C.V.2
Mukherjee, B.3
-
136
-
-
2342658475
-
New targeted therapies in breast cancer
-
Kaklamani V, O'Regan RM. New targeted therapies in breast cancer. Semin Oncol 2004; 31: S20-5.
-
(2004)
Semin Oncol
, vol.31
, pp. 20-25
-
-
Kaklamani, V.1
O'Regan, R.M.2
-
137
-
-
56749160290
-
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance
-
Spearman AD, Sweet K, Zhou XP, McLennan J, Couch FJ, Toland AE. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol 2008; 26: 5393-400.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5393-5400
-
-
Spearman, A.D.1
Sweet, K.2
Zhou, X.P.3
McLennan, J.4
Couch, F.J.5
Toland, A.E.6
-
138
-
-
33748065304
-
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
-
McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15.
-
(2006)
Cancer Res
, vol.66
, pp. 8109-8115
-
-
McCabe, N.1
Turner, N.C.2
Lord, C.J.3
-
139
-
-
77955923866
-
Metformin: Taking away the candy for cancer?
-
Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010; 46: 2369-80.
-
(2010)
Eur J Cancer
, vol.46
, pp. 2369-2380
-
-
Jalving, M.1
Gietema, J.A.2
Lefrandt, J.D.3
de Jong, S.4
Reyners, A.K.5
Gans, R.O.6
-
140
-
-
33748118458
-
Neither LKB1 nor AMPK are the direct targets of metformin
-
Hardie DG. Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology 2006; 131: 973.
-
(2006)
Gastroenterology
, vol.131
, pp. 973
-
-
Hardie, D.G.1
-
141
-
-
77950191479
-
Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells
-
Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010; 70: 2465-75.
-
(2010)
Cancer Res
, vol.70
, pp. 2465-2475
-
-
Ben Sahra, I.1
Laurent, K.2
Giuliano, S.3
-
142
-
-
20844449238
-
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
-
Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18: 283-93.
-
(2005)
Mol Cell
, vol.18
, pp. 283-293
-
-
Jones, R.G.1
Plas, D.R.2
Kubek, S.3
-
143
-
-
3342915617
-
AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation
-
Nagata D, Takeda R, Sata M, et al. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004; 110: 444-51.
-
(2004)
Circulation
, vol.110
, pp. 444-451
-
-
Nagata, D.1
Takeda, R.2
Sata, M.3
-
144
-
-
26844527037
-
Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression
-
Igata M, Motoshima H, Tsuruzoe K, et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005; 97: 837-44.
-
(2005)
Circ Res
, vol.97
, pp. 837-844
-
-
Igata, M.1
Motoshima, H.2
Tsuruzoe, K.3
-
145
-
-
39449120283
-
Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide
-
Zhang M, Dong Y, Xu J, et al. Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ Res 2008; 102: 328-37.
-
(2008)
Circ Res
, vol.102
, pp. 328-337
-
-
Zhang, M.1
Dong, Y.2
Xu, J.3
-
146
-
-
84861222690
-
The ancient drug salicylate directly activates AMP-activated protein kinase
-
Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012; 336: 918-22.
-
(2012)
Science
, vol.336
, pp. 918-922
-
-
Hawley, S.A.1
Fullerton, M.D.2
Ross, F.A.3
-
147
-
-
77956415337
-
Metformin prevents tobacco carcinogen--induced lung tumorigenesis
-
Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) 2010; 3: 1066-76.
-
(2010)
Cancer Prev Res (Phila)
, vol.3
, pp. 1066-1076
-
-
Memmott, R.M.1
Mercado, J.R.2
Maier, C.R.3
Kawabata, S.4
Fox, S.D.5
Dennis, P.A.6
-
148
-
-
84866322945
-
Investigating metformin for cancer prevention and treatment: The end of the beginning
-
Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012; 2: 778-90.
-
(2012)
Cancer Discov
, vol.2
, pp. 778-790
-
-
Pollak, M.N.1
-
149
-
-
33744514139
-
Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome
-
Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006; 3: 403-16.
-
(2006)
Cell Metab
, vol.3
, pp. 403-416
-
-
Cool, B.1
Zinker, B.2
Chiou, W.3
-
150
-
-
36348978499
-
Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family
-
Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 2007; 282: 32539-48.
-
(2007)
J Biol Chem
, vol.282
, pp. 32539-32548
-
-
Sanders, M.J.1
Ali, Z.S.2
Hegarty, B.D.3
Heath, R.4
Snowden, M.A.5
Carling, D.6
-
151
-
-
36348998521
-
Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase
-
Göransson O, McBride A, Hawley SA, et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 2007; 282: 32549-60.
-
(2007)
J Biol Chem
, vol.282
, pp. 32549-32560
-
-
Göransson, O.1
McBride, A.2
Hawley, S.A.3
-
152
-
-
56049112796
-
Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes
-
Scott JW, van Denderen BJ, Jorgensen SB, et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem Biol 2008; 15: 1220-30.
-
(2008)
Chem Biol
, vol.15
, pp. 1220-1230
-
-
Scott, J.W.1
van Denderen, B.J.2
Jorgensen, S.B.3
-
153
-
-
70349921265
-
A-769662 activates AMPK beta1-containing complexes but induces glucose uptake through a PI3-kinase-dependent pathway in mouse skeletal muscle
-
Treebak JT, Birk JB, Hansen BF, Olsen GS, Wojtaszewski JF. A-769662 activates AMPK beta1-containing complexes but induces glucose uptake through a PI3-kinase-dependent pathway in mouse skeletal muscle. Am J Physiol Cell Physiol 2009; 297: C1041-52.
-
(2009)
Am J Physiol Cell Physiol
, vol.297
, pp. 1041-1042
-
-
Treebak, J.T.1
Birk, J.B.2
Hansen, B.F.3
Olsen, G.S.4
Wojtaszewski, J.F.5
-
156
-
-
77953527360
-
Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena
-
Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9: 1057-1064.
-
(2010)
Cell Cycle
, vol.9
, pp. 1057-1064
-
-
Martin-Castillo, B.1
Vazquez-Martin, A.2
Oliveras-Ferraros, C.3
Menendez, J.A.4
-
157
-
-
36348950449
-
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells
-
Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-12.
-
(2007)
Cancer Res
, vol.67
, pp. 10804-10812
-
-
Dowling, R.J.1
Zakikhani, M.2
Fantus, I.G.3
Pollak, M.4
Sonenberg, N.5
-
158
-
-
69249162223
-
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth
-
Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009; 69: 6539-45.
-
(2009)
Cancer Res
, vol.69
, pp. 6539-6545
-
-
Kisfalvi, K.1
Eibl, G.2
Sinnett-Smith, J.3
Rozengurt, E.4
-
159
-
-
44849099894
-
The antidiabetic drug metformin exerts an antitumoral effect In vitro and In vivo through a decrease of cyclin D1 level
-
Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect In vitro and In vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-86.
-
(2008)
Oncogene
, vol.27
, pp. 3576-3586
-
-
Ben Sahra, I.1
Laurent, K.2
Loubat, A.3
-
160
-
-
60749108023
-
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
-
Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009; 8: 88-96.
-
(2009)
Cell Cycle
, vol.8
, pp. 88-96
-
-
Vazquez-Martin, A.1
Oliveras-Ferraros, C.2
Menendez, J.A.3
-
161
-
-
67650514082
-
Metformin induces unique biological and molecular responses in triple negative breast cancer cells
-
Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8: 2031-40.
-
(2009)
Cell Cycle
, vol.8
, pp. 2031-2040
-
-
Liu, B.1
Fan, Z.2
Edgerton, S.M.3
-
162
-
-
24644475793
-
Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice
-
Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40: 685-93.
-
(2005)
Exp Gerontol
, vol.40
, pp. 685-693
-
-
Anisimov, V.N.1
Berstein, L.M.2
Egormin, P.A.3
Piskunova, T.S.4
Popovich, I.G.5
Zabezhinski, M.A.6
-
163
-
-
84872529696
-
Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth
-
Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA 2013; 110: 972-7.
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. 972-977
-
-
Hirsch, H.A.1
Iliopoulos, D.2
Struhl, K.3
-
164
-
-
83355163333
-
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models
-
Cheong JH, Park ES, Liang J, et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 2011; 10: 2350-62.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 2350-2362
-
-
Cheong, J.H.1
Park, E.S.2
Liang, J.3
-
165
-
-
84865685190
-
Metformin impairs the growth of liver kinase B1-intact cervical cancer cells
-
Xiao X, He Q, Lu C, et al. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol 2012; 127: 249-55.
-
(2012)
Gynecol Oncol
, vol.127
, pp. 249-255
-
-
Xiao, X.1
He, Q.2
Lu, C.3
-
166
-
-
33751284806
-
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
-
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-73.
-
(2006)
Cancer Res
, vol.66
, pp. 10269-10273
-
-
Zakikhani, M.1
Dowling, R.2
Fantus, I.G.3
Sonenberg, N.4
Pollak, M.5
-
167
-
-
77953653569
-
New roles for the LKB1-NUAK pathway in controlling myosin phosphatase complexes and cell adhesion
-
Zagórska A, Deak M, Campbell DG, et al. New roles for the LKB1-NUAK pathway in controlling myosin phosphatase complexes and cell adhesion. Sci Signal 2010; 3: ra25.
-
(2010)
Sci Signal
, vol.3
-
-
Zagórska, A.1
Deak, M.2
Campbell, D.G.3
-
168
-
-
77955287742
-
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
-
Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010; 11: 390-401.
-
(2010)
Cell Metab
, vol.11
, pp. 390-401
-
-
Kalender, A.1
Selvaraj, A.2
Kim, S.Y.3
-
169
-
-
84873707522
-
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
-
Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494: 256-60.
-
(2013)
Nature
, vol.494
, pp. 256-260
-
-
Miller, R.A.1
Chu, Q.2
Xie, J.3
Foretz, M.4
Viollet, B.5
Birnbaum, M.J.6
-
170
-
-
77954933558
-
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
-
Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010; 120: 2355-69.
-
(2010)
J Clin Invest
, vol.120
, pp. 2355-2369
-
-
Foretz, M.1
Hébrard, S.2
Leclerc, J.3
-
171
-
-
48649085816
-
Regulation of TORC1 by Rag GTPases in nutrient response
-
Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 2008; 10: 935-45.
-
(2008)
Nat Cell Biol
, vol.10
, pp. 935-945
-
-
Kim, E.1
Goraksha-Hicks, P.2
Li, L.3
Neufeld, T.P.4
Guan, K.L.5
-
172
-
-
45849105156
-
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1
-
Sancak Y, Peterson TR, Shaul YD, et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008; 320: 1496-501.
-
(2008)
Science
, vol.320
, pp. 1496-1501
-
-
Sancak, Y.1
Peterson, T.R.2
Shaul, Y.D.3
-
173
-
-
79952538201
-
Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin In vivo
-
Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin In vivo. Oncogene 2011; 30: 1174-82.
-
(2011)
Oncogene
, vol.30
, pp. 1174-1182
-
-
Algire, C.1
Amrein, L.2
Bazile, M.3
David, S.4
Zakikhani, M.5
Pollak, M.6
-
174
-
-
84873584845
-
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin
-
Shackelford DB, Abt E, Gerken L, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013; 23: 143-58.
-
(2013)
Cancer Cell
, vol.23
, pp. 143-158
-
-
Shackelford, D.B.1
Abt, E.2
Gerken, L.3
-
175
-
-
34247881866
-
Interference with energy metabolism by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induces HPV suppression in cervical carcinoma cells and apoptosis in the absence of LKB1
-
Nafz J, De-Castro Arce J, Fleig V, Patzelt A, Mazurek S, Rösl F. Interference with energy metabolism by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induces HPV suppression in cervical carcinoma cells and apoptosis in the absence of LKB1. Biochem J 2007; 403: 501-10.
-
(2007)
Biochem J
, vol.403
, pp. 501-510
-
-
Nafz, J.1
De-Castro Arce, J.2
Fleig, V.3
Patzelt, A.4
Mazurek, S.5
Rösl, F.6
-
176
-
-
84869788946
-
Metformin and the risk of cancer: Time-related biases in observational studies
-
Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012; 35: 2665-73.
-
(2012)
Diabetes Care
, vol.35
, pp. 2665-2673
-
-
Suissa, S.1
Azoulay, L.2
-
177
-
-
84859778293
-
mTOR signaling in growth control and disease
-
Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-93.
-
(2012)
Cell
, vol.149
, pp. 274-293
-
-
Laplante, M.1
Sabatini, D.M.2
-
178
-
-
84884676252
-
Nutrient signaling to mTOR and cell growth
-
Jewell JL, Guan KL. Nutrient signaling to mTOR and cell growth. Trends Biochem Sci 2013; 38: 233-42.
-
(2013)
Trends Biochem Sci
, vol.38
, pp. 233-242
-
-
Jewell, J.L.1
Guan, K.L.2
-
179
-
-
78650510609
-
mTOR: From growth signal integration to cancer, diabetes and ageing
-
Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
-
(2011)
Nat Rev Mol Cell Biol
, vol.12
, pp. 21-35
-
-
Zoncu, R.1
Efeyan, A.2
Sabatini, D.M.3
-
180
-
-
0032486268
-
Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism
-
Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273: 14484-94.
-
(1998)
J Biol Chem
, vol.273
, pp. 14484-14494
-
-
Hara, K.1
Yonezawa, K.2
Weng, Q.P.3
Kozlowski, M.T.4
Belham, C.5
Avruch, J.6
-
181
-
-
0028899789
-
Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes
-
Blommaart EF, Luiken JJ, Blommaart PJ, van Woerkom GM, Meijer AJ. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J Biol Chem 1995; 270: 2320-6.
-
(1995)
J Biol Chem
, vol.270
, pp. 2320-2326
-
-
Blommaart, E.F.1
Luiken, J.J.2
Blommaart, P.J.3
van Woerkom, G.M.4
Meijer, A.J.5
-
182
-
-
84877965001
-
Regulation of mTORC1 and its impact on gene expression at a glance
-
Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci 2013; 126: 1713-9.
-
(2013)
J Cell Sci
, vol.126
, pp. 1713-1719
-
-
Laplante, M.1
Sabatini, D.M.2
-
183
-
-
13844312400
-
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
-
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
-
(2005)
Science
, vol.307
, pp. 1098-1101
-
-
Sarbassov, D.D.1
Guertin, D.A.2
Ali, S.M.3
Sabatini, D.M.4
-
184
-
-
84883556505
-
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
-
Saini KS, Loi S, de Azambuja E, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev 2013; 39: 935-46.
-
(2013)
Cancer Treat Rev
, vol.39
, pp. 935-946
-
-
Saini, K.S.1
Loi, S.2
de Azambuja, E.3
-
185
-
-
7944235758
-
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
-
Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-8.
-
(2004)
Nat Cell Biol
, vol.6
, pp. 1122-1128
-
-
Jacinto, E.1
Loewith, R.2
Schmidt, A.3
-
186
-
-
3342895823
-
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton
-
Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-302.
-
(2004)
Curr Biol
, vol.14
, pp. 1296-1302
-
-
Sarbassov, D.D.1
Ali, S.M.2
Kim, D.H.3
-
187
-
-
84859117806
-
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity
-
Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335: 1638-43.
-
(2012)
Science
, vol.335
, pp. 1638-1643
-
-
Lamming, D.W.1
Ye, L.2
Katajisto, P.3
-
189
-
-
84883787742
-
mTOR kinase inhibitors as potential cancer therapeutic drugs
-
Sun SY. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett 2013; 340: 1-8.
-
(2013)
Cancer Lett
, vol.340
, pp. 1-8
-
-
Sun, S.Y.1
-
190
-
-
84876863294
-
Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer
-
Zhang X, Li XR, Zhang J. Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer. Curr Cancer Drug Targets 2013; 13: 175-87.
-
(2013)
Curr Cancer Drug Targets
, vol.13
, pp. 175-187
-
-
Zhang, X.1
Li, X.R.2
Zhang, J.3
-
191
-
-
84881558888
-
Differentiating mTOR inhibitors in renal cell carcinoma
-
Pal SK, Quinn DI. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev 2013; 39: 709-19.
-
(2013)
Cancer Treat Rev
, vol.39
, pp. 709-719
-
-
Pal, S.K.1
Quinn, D.I.2
-
192
-
-
84872527628
-
mTOR is a key modulator of ageing and age-related disease
-
Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493: 338-45.
-
(2013)
Nature
, vol.493
, pp. 338-345
-
-
Johnson, S.C.1
Rabinovitch, P.S.2
Kaeberlein, M.3
-
193
-
-
38849208347
-
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTENdeficient glioblastoma
-
Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTENdeficient glioblastoma. PLoS Med 2008; 5: e8.
-
(2008)
PLoS Med
, vol.5
-
-
Cloughesy, T.F.1
Yoshimoto, K.2
Nghiemphu, P.3
-
194
-
-
67749110462
-
Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice
-
Robinson J, Lai C, Martin A, Nye E, Tomlinson I, Silver A. Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. J Pathol 2009; 219: 35-40.
-
(2009)
J Pathol
, vol.219
, pp. 35-40
-
-
Robinson, J.1
Lai, C.2
Martin, A.3
Nye, E.4
Tomlinson, I.5
Silver, A.6
-
195
-
-
58749097239
-
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
-
Mahoney CL, Choudhury B, Davies H, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 2009; 100: 370-5.
-
(2009)
Br J Cancer
, vol.100
, pp. 370-375
-
-
Mahoney, C.L.1
Choudhury, B.2
Davies, H.3
-
196
-
-
62749135926
-
Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model
-
Wei C, Amos CI, Zhang N, Zhu J, Wang X, Frazier ML. Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model. Cancer Lett 2009; 277: 149-54.
-
(2009)
Cancer Lett
, vol.277
, pp. 149-154
-
-
Wei, C.1
Amos, C.I.2
Zhang, N.3
Zhu, J.4
Wang, X.5
Frazier, M.L.6
-
197
-
-
84867112902
-
Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis
-
Tanwar PS, Kaneko-Tarui T, Zhang L, Teixeira JM. Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis. Hum Mol Genet 2012; 21: 4394-405.
-
(2012)
Hum Mol Genet
, vol.21
, pp. 4394-4405
-
-
Tanwar, P.S.1
Kaneko-Tarui, T.2
Zhang, L.3
Teixeira, J.M.4
-
198
-
-
84875325305
-
Hsp90, an unlikely ally in the war on cancer
-
Barrott JJ, Haystead TA. Hsp90, an unlikely ally in the war on cancer. FEBS J 2013; 280: 1381-96.
-
(2013)
FEBS J
, vol.280
, pp. 1381-1396
-
-
Barrott, J.J.1
Haystead, T.A.2
-
199
-
-
84865695733
-
Quantitative analysis of hsp90-client interactions reveals principles of substrate recognition
-
Taipale M, Krykbaeva I, Koeva M, et al. Quantitative analysis of hsp90-client interactions reveals principles of substrate recognition. Cell 2012; 150: 987-1001.
-
(2012)
Cell
, vol.150
, pp. 987-1001
-
-
Taipale, M.1
Krykbaeva, I.2
Koeva, M.3
-
201
-
-
18444404925
-
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy
-
Citri A, Alroy I, Lavi S, et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 2002; 21: 2407-17.
-
(2002)
EMBO J
, vol.21
, pp. 2407-2417
-
-
Citri, A.1
Alroy, I.2
Lavi, S.3
-
202
-
-
0033863883
-
The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome
-
An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000; 11: 355-60.
-
(2000)
Cell Growth Differ
, vol.11
, pp. 355-360
-
-
An, W.G.1
Schulte, T.W.2
Neckers, L.M.3
-
203
-
-
0035877701
-
Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen-activated protein kinase superfamily
-
Miyata Y, Ikawa Y, Shibuya M, Nishida E. Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen-activated protein kinase superfamily. J Biol Chem 2001; 276: 21841-48.
-
(2001)
J Biol Chem
, vol.276
, pp. 21841-21848
-
-
Miyata, Y.1
Ikawa, Y.2
Shibuya, M.3
Nishida, E.4
-
204
-
-
84875519144
-
Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions
-
Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 2013; 39: 375-87.
-
(2013)
Cancer Treat Rev
, vol.39
, pp. 375-387
-
-
Hong, D.S.1
Banerji, U.2
Tavana, B.3
George, G.C.4
Aaron, J.5
Kurzrock, R.6
-
205
-
-
84857994615
-
HSP90 inhibition: Two-pronged exploitation of cancer dependencies
-
Travers J, Sharp S, Workman P. HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discov Today 2012; 17: 242-52.
-
(2012)
Drug Discov Today
, vol.17
, pp. 242-252
-
-
Travers, J.1
Sharp, S.2
Workman, P.3
-
206
-
-
84876717451
-
Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development
-
Soga S, Akinaga S, Shiotsu Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des 2013; 19: 366-76.
-
(2013)
Curr Pharm Des
, vol.19
, pp. 366-376
-
-
Soga, S.1
Akinaga, S.2
Shiotsu, Y.3
-
207
-
-
61449182121
-
Principles of cancer therapy: Oncogene and non-oncogene addiction
-
Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-37.
-
(2009)
Cell
, vol.136
, pp. 823-837
-
-
Luo, J.1
Solimini, N.L.2
Elledge, S.J.3
-
208
-
-
84863652136
-
Circumventing cancer drug resistance in the era of personalized medicine
-
Garraway LA, Janne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012; 2: 214-226.
-
(2012)
Cancer Discov
, vol.2
, pp. 214-226
-
-
Garraway, L.A.1
Janne, P.A.2
-
209
-
-
44649139884
-
Heat shock protein 90 inhibition in lung cancer
-
Shimamura T, Shapiro GI. Heat shock protein 90 inhibition in lung cancer. J Thoracic Oncol 2008; 3: S152-9.
-
(2008)
J Thoracic Oncol
, vol.3
, pp. 152-159
-
-
Shimamura, T.1
Shapiro, G.I.2
-
210
-
-
84860533156
-
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms
-
Paraiso KH, Haarberg HE, Wood E, et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 2012; 18: 2502-14.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2502-2514
-
-
Paraiso, K.H.1
Haarberg, H.E.2
Wood, E.3
-
211
-
-
0037444766
-
Heatshock protein 90 and Cdc37 interact with LKB1 and regulate its stability
-
Boudeau J, Deak M, Lawlor MA, Morrice NA, Alessi DR. Heatshock protein 90 and Cdc37 interact with LKB1 and regulate its stability. Biochem J 2003; 370: 849-57.
-
(2003)
Biochem J
, vol.370
, pp. 849-857
-
-
Boudeau, J.1
Deak, M.2
Lawlor, M.A.3
Morrice, N.A.4
Alessi, D.R.5
-
212
-
-
0346057795
-
Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37
-
Nony P, Gaude H, Rossel M, Fournier L, Rouault JP, Billaud M. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37. Oncogene 2003; 22: 9165-75.
-
(2003)
Oncogene
, vol.22
, pp. 9165-9175
-
-
Nony, P.1
Gaude, H.2
Rossel, M.3
Fournier, L.4
Rouault, J.P.5
Billaud, M.6
-
213
-
-
84860407614
-
Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1
-
Gaude H, Aznar N, Delay A, et al. Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1. Oncogene 2012; 31: 1582-91.
-
(2012)
Oncogene
, vol.31
, pp. 1582-1591
-
-
Gaude, H.1
Aznar, N.2
Delay, A.3
-
214
-
-
84859187259
-
Systematic identification of genomic markers of drug sensitivity in cancer cells
-
Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570-5.
-
(2012)
Nature
, vol.483
, pp. 570-575
-
-
Garnett, M.J.1
Edelman, E.J.2
Heidorn, S.J.3
-
215
-
-
77649090075
-
Cyclooxygenase-2 and cancer treatment: Understanding the risk should be worth the reward
-
Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010; 16: 1384-90.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1384-1390
-
-
Menter, D.G.1
Schilsky, R.L.2
DuBois, R.N.3
-
216
-
-
39849093868
-
AMP-activated protein kinase is involved in COX-2 expression in response to ultrasound in cultured osteoblasts
-
Hou CH, Tan TW, Tang CH. AMP-activated protein kinase is involved in COX-2 expression in response to ultrasound in cultured osteoblasts. Cell Signal 2008; 20: 978-88.
-
(2008)
Cell Signal
, vol.20
, pp. 978-988
-
-
Hou, C.H.1
Tan, T.W.2
Tang, C.H.3
-
218
-
-
2942574455
-
Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2
-
Prosperi JR, Mallery SR, Kigerl KA, Erfurt AA, Robertson FM. Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2. Prostaglandins Other Lipid Mediat 2004; 73: 249-64.
-
(2004)
Prostaglandins Other Lipid Mediat
, vol.73
, pp. 249-264
-
-
Prosperi, J.R.1
Mallery, S.R.2
Kigerl, K.A.3
Erfurt, A.A.4
Robertson, F.M.5
-
219
-
-
56749159779
-
UVB irradiation regulates Cox-2 mRNA stability through AMPK and HuR in human keratinocytes
-
Zhang J, Bowden GT. UVB irradiation regulates Cox-2 mRNA stability through AMPK and HuR in human keratinocytes. Mol Carcinog 2008; 47: 974-83.
-
(2008)
Mol Carcinog
, vol.47
, pp. 974-983
-
-
Zhang, J.1
Bowden, G.T.2
-
220
-
-
0030606299
-
Suppression of intestinal polyposis in Apc 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
-
Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-9.
-
(1996)
Cell
, vol.87
, pp. 803-809
-
-
Oshima, M.1
Dinchuk, J.E.2
Kargman, S.L.3
-
221
-
-
0034796261
-
Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc 716 knockout mice
-
Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc 716 knockout mice. Nat Med 2001; 7: 1048-51.
-
(2001)
Nat Med
, vol.7
, pp. 1048-1051
-
-
Sonoshita, M.1
Takaku, K.2
Sasaki, N.3
-
222
-
-
0034098691
-
Biology of the adenomatous polyposis coli tumor suppressor
-
Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000; 18: 1967-79.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1967-1979
-
-
Goss, K.H.1
Groden, J.2
-
223
-
-
1542269250
-
Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas
-
Takeda H, Miyoshi H, Tamai Y, Oshima M, Taketo MM. Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas. Br J Cancer 2004; 90: 701-4.
-
(2004)
Br J Cancer
, vol.90
, pp. 701-704
-
-
Takeda, H.1
Miyoshi, H.2
Tamai, Y.3
Oshima, M.4
Taketo, M.M.5
-
224
-
-
33845411885
-
The LKB1 tumor suppressor kinase in human disease
-
Katajisto P, Vallenius T, Vaahtomeri K, et al. The LKB1 tumor suppressor kinase in human disease. Bioch Biophys 2007; 1775: 63-75.
-
(2007)
Bioch Biophys
, vol.1775
, pp. 63-75
-
-
Katajisto, P.1
Vallenius, T.2
Vaahtomeri, K.3
-
225
-
-
0344862109
-
Correlation of staining for LKB1 and COX-2 in hamartomatous polyps and carcinomas from patients with Peutz-Jeghers syndrome
-
Wei C, Amos CI, Rashid A, et al. Correlation of staining for LKB1 and COX-2 in hamartomatous polyps and carcinomas from patients with Peutz-Jeghers syndrome. J Histochem Cytochem 2003; 51: 1665-72.
-
(2003)
J Histochem Cytochem
, vol.51
, pp. 1665-1672
-
-
Wei, C.1
Amos, C.I.2
Rashid, A.3
-
226
-
-
12444302178
-
Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas
-
De Leng WW, Westerman AM, Weterman MA, et al. Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin Cancer Res 2003; 9: 3065-72.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 3065-3072
-
-
De Leng, W.W.1
Westerman, A.M.2
Weterman, M.A.3
-
227
-
-
0037343907
-
Overexpression of cyclooxygenase 2 in hamartomatous polyps of Peutz-Jeghers syndrome
-
McGarrity TJ, Peiffer LP, Amos CI, Frazier ML, Ward MG, Howett MK. Overexpression of cyclooxygenase 2 in hamartomatous polyps of Peutz-Jeghers syndrome. Am J Gastroenterol 2003; 98: 671-8.
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 671-678
-
-
McGarrity, T.J.1
Peiffer, L.P.2
Amos, C.I.3
Frazier, M.L.4
Ward, M.G.5
Howett, M.K.6
-
228
-
-
41349114071
-
LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis
-
Katajisto P, Vaahtomeri K, Ekman N, et al. LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet 2008; 40: 455-9.
-
(2008)
Nat Genet
, vol.40
, pp. 455-459
-
-
Katajisto, P.1
Vaahtomeri, K.2
Ekman, N.3
-
229
-
-
5144232989
-
Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2
-
Udd L, Katajisto P, Rossi DJ, et al. Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. Gastroenterology 2004; 127: 1030-7.
-
(2004)
Gastroenterology
, vol.127
, pp. 1030-1037
-
-
Udd, L.1
Katajisto, P.2
Rossi, D.J.3
-
230
-
-
0041438603
-
Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis
-
Takeda H, Sonoshita M, Oshima H, et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 2003; 63: 4872-7.
-
(2003)
Cancer Res
, vol.63
, pp. 4872-4877
-
-
Takeda, H.1
Sonoshita, M.2
Oshima, H.3
-
231
-
-
78650746613
-
LKB1/PEA3/αNp63 pathway regulates PTGS-2 (COX-2) transcription in lung cancer cells upon cigarette smoke exposure
-
Ratovitski EA. LKB1/PEA3/αNp63 pathway regulates PTGS-2 (COX-2) transcription in lung cancer cells upon cigarette smoke exposure. Oxid Med Cell Longev 2010; 3: 317-24.
-
(2010)
Oxid Med Cell Longev
, vol.3
, pp. 317-324
-
-
Ratovitski, E.A.1
-
232
-
-
84879074624
-
Liver Kinase B1 Is Required for Thromboxane Receptor-Dependent Nuclear Factor-βB Activation and Inflammatory Responses
-
He J, Zhou Y, Xing J, et al. Liver Kinase B1 Is Required for Thromboxane Receptor-Dependent Nuclear Factor-βB Activation and Inflammatory Responses. Arterioscler Thromb Vasc Biol 2013; 33: 1297-305.
-
(2013)
Arterioscler Thromb Vasc Biol
, vol.33
, pp. 1297-1305
-
-
He, J.1
Zhou, Y.2
Xing, J.3
-
233
-
-
82055161852
-
Cyclooxygenase as a target for colorectal cancer chemoprevention
-
Moreira L, Castells A. Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets 2011; 12: 1888-94.
-
(2011)
Curr Drug Targets
, vol.12
, pp. 1888-1894
-
-
Moreira, L.1
Castells, A.2
-
234
-
-
41349104451
-
Chemoprevention of colorectal neoplasia: The potential for personalized medicine
-
Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008; 134: 1224-37.
-
(2008)
Gastroenterology
, vol.134
, pp. 1224-1237
-
-
Arber, N.1
Levin, B.2
-
235
-
-
76849095665
-
The role of COX-2 in intestinal inflammation and colorectal cancer
-
Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-8.
-
(2010)
Oncogene
, vol.29
, pp. 781-788
-
-
Wang, D.1
Dubois, R.N.2
-
236
-
-
66849099322
-
Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis
-
Zuo X, Peng Z, Moussalli MJ, et al. Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst 2009; 101: 762-767.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 762-767
-
-
Zuo, X.1
Peng, Z.2
Moussalli, M.J.3
-
237
-
-
0037081194
-
Cyclooxygenase 2-and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps
-
Seno H, Oshima M, Ishikawa TO, et al. Cyclooxygenase 2-and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res 2002; 62: 506-11.
-
(2002)
Cancer Res
, vol.62
, pp. 506-511
-
-
Seno, H.1
Oshima, M.2
Ishikawa, T.O.3
-
238
-
-
0035903028
-
Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice
-
Ylikorkala A, Rossi DJ, Korsisaari N, et al. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science 2001; 293: 1323-6.
-
(2001)
Science
, vol.293
, pp. 1323-1326
-
-
Ylikorkala, A.1
Rossi, D.J.2
Korsisaari, N.3
-
239
-
-
84885094670
-
N-Methylnitrosourea aggravates gastrointestinal polyposis in Lkb1+/-mice
-
Udd L, Gao Y, Ristimäki AP, Mäkelä TP. N-Methylnitrosourea aggravates gastrointestinal polyposis in Lkb1+/-mice. Carcinogenesis 2013; 34(10): 2409-14.
-
(2013)
Carcinogenesis
, vol.34
, Issue.10
, pp. 2409-2414
-
-
Udd, L.1
Gao, Y.2
Ristimäki, A.P.3
Mäkelä, T.P.4
-
240
-
-
17744418769
-
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
-
Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
-
(2000)
N Engl J Med
, vol.342
, pp. 1946-1952
-
-
Steinbach, G.1
Lynch, P.M.2
Phillips, R.K.S.3
-
241
-
-
0038070069
-
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice
-
Saukkonen K, Tomasetto C, Narko K, Rio MC, Ristimaki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res 2003; 63: 3032-6.
-
(2003)
Cancer Res
, vol.63
, pp. 3032-3036
-
-
Saukkonen, K.1
Tomasetto, C.2
Narko, K.3
Rio, M.C.4
Ristimaki, A.5
-
243
-
-
77955505020
-
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis
-
Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther 2010; 9: 2322-32.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2322-2332
-
-
Nagaraj, N.S.1
Smith, J.J.2
Revetta, F.3
Washington, M.K.4
Merchant, N.B.5
-
244
-
-
84872684334
-
Estrogen receptor signaling as a target for novel breast cancer therapeutics
-
Renoir JM, Marsaud V, Lazennec G. Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol 2013; 85: 449-65.
-
(2013)
Biochem Pharmacol
, vol.85
, pp. 449-465
-
-
Renoir, J.M.1
Marsaud, V.2
Lazennec, G.3
-
245
-
-
77950491674
-
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
-
Haura EB, Tanvetyanon T, Chiappori A, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1387-94.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1387-1394
-
-
Haura, E.B.1
Tanvetyanon, T.2
Chiappori, A.3
-
246
-
-
54549086723
-
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530
-
Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008; 27: 6365-75.
-
(2008)
Oncogene
, vol.27
, pp. 6365-6375
-
-
Chang, Y.M.1
Bai, L.2
Liu, S.3
Yang, J.C.4
Kung, H.J.5
Evans, C.P.6
-
247
-
-
77953238558
-
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors
-
Carretero J, Shimamura T, Rikova K, et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010; 17: 547-59.
-
(2010)
Cancer Cell
, vol.17
, pp. 547-559
-
-
Carretero, J.1
Shimamura, T.2
Rikova, K.3
-
248
-
-
31144459985
-
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
-
Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-7.
-
(2006)
Nature
, vol.439
, pp. 353-357
-
-
Bild, A.H.1
Yao, G.2
Chang, J.T.3
-
249
-
-
57349194139
-
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
-
Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-6.
-
(2008)
Nat Med
, vol.14
, pp. 1351-1356
-
-
Engelman, J.A.1
Chen, L.2
Tan, X.3
-
250
-
-
77953239772
-
LKB1 and Src: Antagonistic regulators of tumor growth and metastasis
-
Slack-Davis J, Dasilva JO, Parsons SJ. LKB1 and Src: antagonistic regulators of tumor growth and metastasis. Cancer Cell 2010; 17: 527-9.
-
(2010)
Cancer Cell
, vol.17
, pp. 527-529
-
-
Slack-Davis, J.1
Dasilva, J.O.2
Parsons, S.J.3
-
251
-
-
58649110598
-
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation
-
Zheng B, Jeong JH, Asara JM, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009; 33: 237-47.
-
(2009)
Mol Cell
, vol.33
, pp. 237-247
-
-
Zheng, B.1
Jeong, J.H.2
Asara, J.M.3
-
252
-
-
62849094740
-
Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF
-
Esteve-Puig R, Canals F, Colomé N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One 2009; 4: e4771.
-
(2009)
PLoS One
, vol.4
-
-
Esteve-Puig, R.1
Canals, F.2
Colomé, N.3
Merlino, G.4
Recio, J.A.5
-
253
-
-
58749097239
-
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
-
Mahoney CL, Choudhury B, Davies H, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 2009; 100: 370-5.
-
(2009)
Br J Cancer
, vol.100
, pp. 370-375
-
-
Mahoney, C.L.1
Choudhury, B.2
Davies, H.3
-
254
-
-
84881508779
-
Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target in LKB1 Mutant Lung Cancer
-
Liu Y, Marks K, Cowley GS, et al. Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target in LKB1 Mutant Lung Cancer. Cancer Discov 2013; 3: 870-879.
-
(2013)
Cancer Discov
, vol.3
, pp. 870-879
-
-
Liu, Y.1
Marks, K.2
Cowley, G.S.3
-
255
-
-
20244388673
-
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage
-
Syljuåsen RG, Sørensen CS, Hansen LT, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005; 25: 3553-62.
-
(2005)
Mol Cell Biol
, vol.25
, pp. 3553-3562
-
-
Syljuåsen, R.G.1
Sørensen, C.S.2
Hansen, L.T.3
-
256
-
-
79651470785
-
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
-
Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011; 17: 88-96.
-
(2011)
Trends Mol Med
, vol.17
, pp. 88-96
-
-
Ma, C.X.1
Janetka, J.W.2
Piwnica-Worms, H.3
-
257
-
-
65449142073
-
CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors
-
Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009; 8: 24.
-
(2009)
Mol Cancer
, vol.8
, pp. 24
-
-
Chen, C.C.1
Kennedy, R.D.2
Sidi, S.3
Look, A.T.4
D'Andrea, A.5
-
258
-
-
79955686677
-
CHK1 inhibitors in combination chemotherapy: Thinking beyond the cell cycle
-
Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv 2011; 11: 133-40.
-
(2011)
Mol Interv
, vol.11
, pp. 133-140
-
-
Dent, P.1
Tang, Y.2
Yacoub, A.3
Dai, Y.4
Fisher, P.B.5
Grant, S.6
-
259
-
-
34247481285
-
Targeting checkpoint kinase 1 in cancer therapeutics
-
Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13: 1955-60.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1955-1960
-
-
Tse, A.N.1
Carvajal, R.2
Schwartz, G.K.3
-
260
-
-
0023925454
-
Interactions between deoxyribonucleotide and DNA synthesis
-
Reichard P. Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem 1988; 57: 349-74.
-
(1988)
Annu Rev Biochem
, vol.57
, pp. 349-374
-
-
Reichard, P.1
-
261
-
-
0031725620
-
Thymine metabolism and thymineless death in prokaryotes and eukaryotes
-
Ahmad SI, Kirk SH, Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol 1998; 52: 591-625.
-
(1998)
Annu Rev Microbiol
, vol.52
, pp. 591-625
-
-
Ahmad, S.I.1
Kirk, S.H.2
Eisenstark, A.3
-
262
-
-
84862777541
-
A murine lung cancer coclinical trial identifies genetic modifiers of therapeutic response
-
Chen Z, Cheng K, Walton Z, et al. A murine lung cancer coclinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483: 613-7.
-
(2012)
Nature
, vol.483
, pp. 613-617
-
-
Chen, Z.1
Cheng, K.2
Walton, Z.3
|